5AM Ventures, of Menlo Park, Calif., added Scott Rocklage as venture partner.
Aastrom Biosciences Inc., of Ann Arbor, appointed Herbert Schwartz to its technology review board.
Aerogen Inc., of Mountain View, Calif., promoted Angela Strand to vice president, marketing.
Amgen Inc., of Thousand Oaks, Calif., named Christian Fibiger vice president and global therapeutic area head for neuroscience research and appointed Paul Pearson vice president of pharmacokinetics and drug metabolism.
Atrix Laboratories Inc., of Fort Collins, Colo., elected Richard Vietor to its board.
BioReliance Corp., of Rockville, Md., named John Coker senior vice president, finance and administration; chief financial officer; secretary and treasurer. Raymond Cosgrove was promoted to senior vice president, Europe and international. Allan Darling was named senior vice president, U.S. biologics and LAHS.
Borean Pharma, of Aarhus, Denmark, appointed Johanna Holldack chief operating officer.
Boston Life Sciences Inc., of Boston, named Marc Lanser president and chief operating officer.
C.K. Cooper & Co., of San Francisco, appointed Mikael van Loon managing director, life sciences group.
Cephalon Inc., of West Chester, Pa., added Victor Raczkowski as vice president, worldwide regulatory affairs.
Cylex Inc., of Columbia, Md., added Timothy Ellis as president.
CytRx Corp., of Los Angeles, elected Marvin Selter and Richard Wennekamp to its board.
Genentech Inc., of South San Francisco, promoted Diane Parks to senior vice president and general manager, specialty therapeutics and managed care. It also promoted Vishva Dixit to vice president, research, molecular oncology.
Hemispherx Biopharma Inc., of Philadelphia, appointed Anthony Komaroff to its scientific advisory board.
Inimex Pharmaceuticals Inc., of Vancouver, British Columbia, formed its scientific and medical advisory board, consisting of Anthony Chow, Gordon Dougan, Stanley Falkow, Brett Finlay, Walter Singleton and Grant Stiver.